<DOC>
	<DOC>NCT02132169</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety of AC-170 0.24% used twice daily in Healthy Adult Subjects and in Pediatric subjects with a history or family history of atopic disease (including allergic conjunctivitis).</brief_summary>
	<brief_title>A Multi-Center Study Evaluating the Safety of AC-170 0.24%</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis, Allergic</mesh_term>
	<mesh_term>Cetirizine</mesh_term>
	<criteria>at least 2 years of age be able to selfadminister eye drops or have a parent/legal guardian available for this purpose if less than 18 years old have a history or family history of atopic disease (including allergic conjunctivitis) have ocular health within normal limits known contraindications or sensitivities to the study medication or its components any ocular condition that, in the opinion of the investigator, could affect the subjects safety trial parameters use of disallowed medication during the period indicated prior to the enrollment or during the study</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>